DMX-200 Phase 3 Trial Achieves Full Adult Patient Enrollment, Marking Critical Milestone for FSGS Treatment

Dimerix Limited (DXB.AX) has successfully wrapped up adult patient recruitment for its ACTION3 Phase 3 clinical trial investigating DMX-200 as a therapeutic intervention for focal segmental glomerulosclerosis (FSGS). The company dosed its 286th and final adult participant, advancing the development timeline toward potential regulatory approval in this severely underserved patient population.

Understanding the Clinical Challenge

Focal segmental glomerulosclerosis represents a degenerative kidney disorder in which scar tissue progressively damages the nephrons responsible for blood filtration. The condition inevitably leads to protein leakage in urine (proteinuria) and, without intervention, deteriorates to end-stage renal disease requiring dialysis or transplantation. Existing therapeutic arsenal remains limited, leaving many patients with few alternatives as kidney function gradually declines.

Trial Design and Patient Response

The ACTION3 study operates as a multicenter, double-blind, placebo-controlled investigation comparing DMX-200 added to standard angiotensin II receptor blocker (ARB) therapy against placebo alone. Adult participants receive either DMX-200 (120 mg capsule administered twice daily) or matching placebo over a 24-month observation window. The trial’s primary success metrics center on reducing proteinuria levels and stabilizing kidney filtration rates, assessed through eGFR slope measurements.

Of the 286 enrolled adults, 69 participants have already completed the full two-year treatment protocol. Notably, 65 of these completers voluntarily transitioned into the open-label extension phase—a striking 94% continuation rate that suggests strong safety and tolerability signals.

Regulatory Progress and Next Steps

The ACTION3 investigation has successfully cleared seven independent Data Monitoring Committee reviews, with no protocol modifications or safety red flags identified. This clean safety profile strengthens the trial’s credibility as it progresses toward data lock.

Dimerix and its U.S. collaborator Amicus Therapeutics are leveraging insights from the PARASOL global initiative—which validated proteinuria as a clinically meaningful endpoint—to inform their FDA engagement strategy. Before conducting the blinded analysis of ACTION3 data, the companies plan to seek regulatory feedback on their proposed trial endpoints, optimizing the pathway toward potential approval.

Pediatric patient recruitment continues as a separate cohort, and if positive results emerge, DMX-200 could eventually expand into adolescent populations across key markets, broadening its therapeutic reach.

Market Position and Cash Runway

Dimerix maintains sufficient cash reserves to sustain ACTION3 operations through completion, while simultaneously evaluating emerging R&D opportunities in its pipeline. The company’s stock (DXB.AX) closed at AU$0.60, up 0.83%, having fluctuated between AU$0.30 and AU$0.78 over the preceding 12 months.